admin – Page 5265 – Get News Story

Alzheimer’s disease Treatment Market Size in the 7MM was ~USD 3,500 Million in 2022, estimated DelveInsight

Alzheimer’s Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Alzheimer’s Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Alzheimer’s Disease Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Alzheimer’s Disease, historical and forecasted epidemiology as well as the Alzheimer’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Alzheimer’s Disease Market by downloading the comprehensive report from DelveInsight @ Alzheimer’s Disease Treatment Market Size

Key Takeaways from the Alzheimer’s Disease Market Report

In October 2024:- ACADIA Pharmaceuticals Inc.- A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer’s Disease Psychosis. This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP.
In October 2024:- AriBio Co., Ltd.- A Phase 3 Double-blind, Randomized, Placebo-controlled, Multi-center Trial to Evaluate the Efficacy and Safety of AR1001 Over 52 Weeks in Participants with Early Alzheimer’s Disease (Polaris-AD). The purpose of this Study is to evaluate the efficacy and safety of AR1001 in participants with Early Alzheimer’s Disease (AD).
The projected growth in Alzheimer’s Disease market size is mainly driven by increasing diagnosed prevalence, increasing awareness, and improved diagnosis along with anticipated approval of emerging therapies in the 7MM.
As per DelveInsight analysis, in 2023, there were approximately 15.4 million total diagnosed prevalent cases of Alzheimer’s disease in the 7MM. These cases are projected to increase further during the forecast period, due to increasing geriatric population globally.
According to DelveInsight’s analysis of Alzheimer’s disease by severity, in 2023, there were approximately 8.4, 3.2, 2.3, and 1.5 million cases of MCI, mild, moderate, and severe dementia, respectively, across the 7MM, which are expected to increase by 2034.
As per estimates based on DelveInsight’s epidemiology model for Alzheimer’s disease, the gender distribution of the disease suggests a female predominance across the 7MM, with approximately 5.1 million male and 10 million female cases in the 7MM, in 2023.
The leading Alzheimer’s Disease Companies such as Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.
Promising Alzheimer’s Disease Therapies such as Wujia Yizhi granules, Semaglutide, Gantenerumab, E2814, Lecanemab, and others.

Gain a competitive edge in the Alzheimer’s Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Alzheimer’s Disease Treatment Drugs

Alzheimer’s Disease Epidemiology Segmentation in the 7MM

Alzheimer’s Disease Age-specific Cases
Total Alzheimer’s Disease Diagnosed Prevalent Cases
Alzheimer’s Disease Gender-specific Cases
Alzheimer’s Disease Severity-specific Cases

Alzheimer’s Disease Market Insights

There is currently no cure for Alzheimer’s disease, even though early initiation and treatment persistence is considered important in relieving the clinical symptoms of Alzheimer’s disease. Earlier diagnosis is important for enabling symptomatic therapies, treating behavioral symptoms, and adopting lifestyle changes commonly used to reduce the risk of developing dementia and eventually slow disease progression.

Discover key developments and opportunities in the Alzheimer’s Disease Market. Click here to learn more from DelveInsight’s latest report @ Alzheimer’s Disease Market Size

Marketed Alzheimer’s disease Drugs

ADUHELM (aducanumab): Biogen and Eisai
LEQEMBI (lecanemab): Biogen and Eisai
Donanemab (LY3002813): Eli Lilly

Emerging Alzheimer’s disease Drugs

NE3107: BioVie
Simufilam (PTI-125): Cassava Sciences
Hydromethylthionine mesylate/TRx0237: TauRx Therapeutics
ALZ-801 (valiltramiprosate): Alzheon
Fosgonimeton (ATH-1017): Athira Pharma
Buntanetap: Annovis Bio
ANAVEX2-73 (blarcamesine): Anavex Life Sciences

Alzheimer’s Disease Market Outlook

The drugs currently available to treat many of the symptoms associated with dementia are working by increasing activity levels of some brain neurotransmitters, such as acetylcholine, serotonin, and noradrenaline, or by reducing the activity of other neurotransmitters, such as glutamate and dopamine. Due to associated side effects, it is also important to personalize dementia symptomatic therapeutics considering patients’ comorbidities and their respective therapies. Effects on cardiac function, drug elimination, and other interactions should be assessed case by case.

Download DelveInsight’s Alzheimer’s Disease Market report today and stay ahead in this rapidly evolving field. @ Alzheimer’s Disease Clinical Trials

Scope of the Alzheimer’s Disease Market Report

Coverage- 7MM
Alzheimer’s Disease Companies- Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., and others.
Alzheimer’s Disease Therapies- Wujia Yizhi granules, Semaglutide, Gantenerumab, E2814, Lecanemab, and others.
Alzheimer’s Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Alzheimer’s Disease Unmet Needs, KOL’s views, Analyst’s views, Alzheimer’s Disease Market Access and Reimbursement

Download the report to understand which factors are driving Alzheimer’s Disease Market Trends @ Alzheimer’s Disease Market Trends

Table of Content

1. Key Insights

2. Report Introduction

3. Alzheimer’s Disease Market Overview at a Glance

4. Methodology of Alzheimer’s Disease Epidemiology and Market

5. Executive Summary of Alzheimer’s Disease

6. Key events

7. Disease Background and Overview

8. Alzheimer’s Disease Patient Journey of Alzheimer’s Disease

9. Alzheimer’s Disease Epidemiology and Patient Population

10. Alzheimer’s Disease Marketed Drugs

11. Emerging Alzheimer’s Disease Therapies

12. Alzheimer’s Disease Market: The Seven Major Market Analysis

13. Alzheimer’s Disease KOL views

14. SWOT Analysis

15. Alzheimer’s Disease Unmet Needs

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alzheimer’s disease Treatment Market Size in the 7MM was ~USD 3,500 Million in 2022, estimated DelveInsight

Sulfur Dust Market 2024 Demand Status, Growth Dynamic, Key Players, Business Prospects, Development Strategies and Industry Challenges

“Browse 151 market data Tables and 37 Figures spread through 154 Pages and in-depth TOC on “Sulfur Dust Market”

The Sulfur Dust Market is expected to witness steady growth, driven by its increasing use in agriculture as a fungicide and pesticide. Sulfur dust is widely utilized in the control of fungal diseases in crops, enhancing agricultural yields. The Asia-Pacific region, especially countries like China and India, is anticipated to lead market expansion due to its strong agricultural base.

The global sulfur dust market is projected to decline from USD 1.3 billion in 2023 to USD 1.1 billion by 2028, at a CAGR of -3.0% during the forecast period. The sulfur dust market is driven by its wide range of applications in different sectors. Sulfur dust is widely used in agriculture as a vital ingredient in fertilizers, enhancing crop output and improving soil fertility. It also plays a major role in the rubber, chemical, and pharmaceutical industries for vulcanization, drug production, and chemical synthesis, respectively. Moreover, the market’s expansion is also fueled by the world’s growing need for agrochemicals, the growing emphasis on sustainable farming methods, increased R&D expenditure in the fields of renewable energy and electric vehicles (EVs), as well as growing popularity as a dermatological element in the pharmaceutical industry.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=177296162

By form, the precipitated sulfur accounted is expected to account for the largest share of the Sulfur Dust Market during the forecast period, in terms of volume.

Precipitated sulfur in sulfur dust market is accounted for the largest segment in terms of value. This dominance is attributed to several key advantages of precipitated sulfur. Precipitated sulfur form plays a significant role in various applications across pharmaceutical, industrial, agricultural, and other sectors, owing to its diverse range of properties and functions. This versatility is a crucial factor in growing demand of precipitated sulfur in sulfur dust across various industries.

By end use industry, agriculture are expected to account for the largest market share during the forecast period in terms of volume.

Agriculture is accounted for the largest segment, in terms of value in the sulfur dust market during the forecast period. Sulfur dust finds its largest application share in agriculture due to its vital role as a nutrient for plant growth, pH adjustment properties, and effectiveness in controlling diseases and pests. Farmers commonly use sulfur dust as a fertilizer to enhance soil fertility and crop yields while also benefiting from its environmentally friendly nature compared to synthetic alternatives.

Get Sample Copy of this Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=177296162

Asia Pacific is projected to register the largest market share during the forecast period.

The Asia-Pacific region holds the largest share in the sulfur dust market primarily due to the growth in agriculture. This dominance is driven by the increasing demand for sulfur in fertilizer and rubber processing from countries like China and India. The rising demand for sulfur-based fertilizers from agricultural countries like India, China, Japan, and Kazakhstan contributes to the region’s market leadership. Additionally, favorable government policies supporting sulfur production in countries such as China, India, and Japan further enhance the Asia-Pacific region’s position in the sulfur market.

Sulfur Dust Market Key Players

The major market players include Grupa Azoty (Poland), Jaishil Sulfur and Chemical Industries (India), Jordan Sulfur (Jordan), SML Limited (India), Saeed Ghodran Group (Saudi Arabia), American Elements (US), Solar Chemferts (India), Maruti Corporation (India), Shandong Hubin Rubber Technology Co., Ltd. (China), Georgia Gulf Sulfur Corporation (Georgia) are the leading players in the market. There is significant competition in the sulfur dust market to develop new process technology, lower the manufacturing cost, expand, and increase the use of sulfur in the end-use industries. Owing to such opportunities in the industry, companies are aiming to enhance their market shares by adopting various strategies.

About MarketsandMarkets™

MarketsandMarkets™ has been recognized as one of America’s best management consulting firms by Forbes, as per their recent report.

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

Earlier this year, we made a formal transformation into one of America’s best management consulting firms as per a survey conducted by Forbes.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the ‘GIVE Growth’ principle, we work with several Forbes Global 2000 B2B companies – helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/sulfur-dust-market-177296162.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sulfur Dust Market 2024 Demand Status, Growth Dynamic, Key Players, Business Prospects, Development Strategies and Industry Challenges

Epilepsy Treatment Market Size in the 7MM was ~USD 9 billion in 2023, estimated DelveInsight

Epilepsy Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Epilepsy Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Epilepsy Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Epilepsy Market by downloading the comprehensive report from DelveInsight @ Epilepsy Treatment Market Size

Key Takeaways from the Epilepsy Market Report

In October 2024:- A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy. The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
In October 2024:- Jazz Pharmaceuticals- A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution. This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.
In October 2024:- Hoffmann-La Roche- The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of epilepsy were nearly 7 million in the 7MM. These cases are projected to increase due to the increased aging global population where older adults are more susceptible to conditions such as stroke, dementia, and epilepsy during the forecast period (2024-2034).
In 2023, among the 7MM, the US accounted for approximately 3 million total diagnosed prevalent cases of epilepsy, of which nearly 14% of cases were diagnosed in children and 86% in adults; the total cases of epilepsy are expected to increase by 2034.
The US had the highest cases of epilepsy, of which nearly 67% of the cases were focal epileptic seizures, 31% were generalized epileptic seizures, while 2% of the cases were other determined or undetermined epileptic seizures.
The leading Epilepsy Companies such as Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
Promising Epilepsy Therapies such as Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.

Gain a competitive edge in the Epilepsy Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Epilepsy Treatment Drugs

Epilepsy Epidemiology Segmentation in the 7MM

Total Diagnosed Prevalent Cases
Gender-specific Diagnosed Prevalent Cases
Diagnosed Prevalent Cases of Epilepsy Based on Seizure Type
Diagnosed Cases of Other Types of Epilepsies and Associated Diseases

Epilepsy Treatment Market

The Epilepsy treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient’s condition and the severity of the case. Epilepsy treatment involves various drug classes to control seizures, including sodium channel blockers (e.g., phenytoin, lamotrigine), which stabilize neuronal activity by inhibiting abnormal electrical impulses. Calcium channel blockers (e.g., ethosuximide) are effective for absence seizures, while GABAergic agents (e.g., valproate, benzodiazepines) enhance inhibitory neurotransmission to reduce seizure frequency. Newer-generation AEDs like levetiracetam and topiramate offer broader efficacy with fewer side effects, addressing both generalized and focal seizures. Non-pharmacological options such as vagus nerve stimulation (VNS) and the ketogenic diet are also utilized, particularly in drug-resistant cases, providing additional therapeutic avenues.

Discover key developments and opportunities in the Epilepsy Market. Click here to learn more from DelveInsight’s latest report @ Epilepsy Market Size

Epilepsy Marketed Drugs

LIBERVANT (diazepam buccal film): Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)
EPIDIOLEX/EPIDYOLEX (cannabidiol): Jazz Pharmaceuticals
XCOPRI/ONTOZRY (cenobamate): SK Biopharmaceutical/Angelini Pharma/Ono Pharmaceutical
AFINITOR DISPERZ/VOTUBIA (everolimus): Novartis

Epilepsy Emerging Drugs

XEN1101/Azetukalner: Xenon Pharmaceuticals
Soticlestat (TAK-935): Takeda/Ovid Therapeutics

Epilepsy Market Outlook

The treatment paradigm of epilepsy or its management strategies involves three main categories, i.e., pharmacotherapy, surgery, and alternative treatment strategies, including neurostimulation, ketogenic diet, and lifestyle changes. Medical professionals decide the treatment line according to the patient’s condition and the severity of the case.

Download DelveInsight’s Epilepsy Market report today and stay ahead in this rapidly evolving field. @ Epilepsy Clinical Trials

Scope of the Epilepsy Market Report

Coverage- 7MM
Epilepsy Companies- Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven Pharmaceuticals, Knopp Biosciences, UCB Pharma, Alexza Pharmaceuticals, Neurocrine Biosciences, Idorsia Pharmaceuticals, Equilibre Biopharmaceuticals, and others.
Epilepsy Therapies- Satralizumab, GWP42003-P, Cannabidiol, Carisbamate, XEN1101, Ganaxalone, and others.
Epilepsy Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Epilepsy Unmet Needs, KOL’s views, Analyst’s views, Epilepsy Market Access and Reimbursement

Download the report to understand which factors are driving Epilepsy Market Trends @ Epilepsy Market Trends

Table of Content

1 Key Insights

2 Report Introduction

3 Epilepsy Market Overview at a Glance

4 Methodology of Epilepsy Epidemiology and Market

5 Executive Summary

6 Key Events

7 Disease Background and Overview

8 Epilepsy Patient Journey

9 Epilepsy Epidemiology and Patient Population

10 Epilepsy Marketed Drugs

11 Epilepsy Emerging Drugs

12 Epilepsy: Market Analysis

13 Key Opinion Leaders’ Views

14 SWOT Analysis

15 Epilepsy Unmet Needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

20 About DelveInsight

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Epilepsy Treatment Market Size in the 7MM was ~USD 9 billion in 2023, estimated DelveInsight

Pressure Sensitive Adhesive Tapes Market to Boost Revenue Potential, Highlight Latest Development and Develop Important Players Profile

“Browse 451 market data Tables and 71 Figures spread through 406 Pages and in-depth TOC on “Pressure Sensitive Adhesive Tapes Market”

The Pressure Sensitive Adhesive (PSA) Tapes Market is experiencing robust growth, driven by rising demand across industries such as packaging, automotive, healthcare, and electronics. Key factors contributing to market expansion include advancements in adhesive technology, increasing applications in lightweight automotive components, and growing e-commerce packaging needs.

The global pressure sensitive adhesive tapes market size is projected to grow from USD 67.0 billion in 2023 to USD 92.4 billion, at a CAGR of 4.7%. The global pressure-sensitive adhesive tapes market has experienced substantial growth in recent years, driven by the increasing diversity of applications across various industries. These tapes, known as pressure sensitive adhesive tapes, have become essential in modern manufacturing due to their ease of use, adaptability, and ability to provide dependable bonding solutions. This overview delves into the key dynamics shaping the pressure-sensitive adhesive tapes market.

The single-sided tapes segment is expected to account for one of the largest shares in 2023.

In the realm of pressure-sensitive adhesive (PSA) tapes, the single-coated variant stands out as a versatile and widely utilized solution. Characterized by the application of adhesive on just one side of the backing material, this design accommodates diverse backing compositions, including paper, polymeric film, foil, nonwoven fabric, or high-thread-count woven cloth. The adhesive formulation in single-coated tapes can vary, featuring compositions such as acrylic, rubber, or silicone, each imparting distinct characteristics to the tape. Single-coated tapes find application across various industries, serving crucial roles in electrical, masking, carton sealing, and medical domains. From facilitating secure carton closures to providing precise and reliable masking in painting applications, the single-coated pressure sensitive adhesive tapes exemplify adaptability and effectiveness in meeting specific industrial requirements. This dynamic tape category continues to evolve, driven by innovations in adhesive technologies and the evolving demands of diverse sectors.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93089164

The water-based segment is expected to account for the largest share in 2023.

Water-based technology stands out as the predominant formulating approach for adhesives when considering volume metrics. Adhesives crafted through this technology primarily involve resin emulsions, notably polyvinyl acetate emulsion (PAE). PAE represents a stable suspension of polyvinyl acetate (PVA) particles in water, often enhanced with water-soluble protective colloids like polyvinyl alcohol or 2-hydroxyethyl cellulose ether. Additional components such as plasticizers, fillers, solvents, defoamers, and preservatives may augment these adhesives, formulated from rubber compounds as the base material. Synthetic hydrocarbon resins or derivatives from pine sap are incorporated to boost strength. This technology employs water as the carrier fluid, suspending adhesive particles and lowering viscosity, facilitating application across diverse substrates and thickness requirements.

Asia Pacific is expected to account for the largest share in 2023.

Beyond driving demand and influencing the global market landscape, Asia Pacific stands out for its proactive approach to sustainability in the pressure-sensitive adhesive tapes industry. The region is witnessing a significant shift toward eco-friendly and recyclable adhesive solutions. Governments and regulatory bodies are actively promoting sustainable practices, leading to increased research and development in bio-based adhesives and environmentally conscious manufacturing processes. This emphasis on sustainability aligns with the growing awareness and preferences of consumers and businesses for eco-friendly products. Consequently, Asia Pacific not only serves as a major consumer and producer but also as a trailblazer in fostering a more sustainable and environmentally responsible future for the pressure-sensitive adhesive tapes sector. This dual role positions the region at the forefront of shaping the industry’s trajectory on a global scale.

Inquire Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=93089164

Key Players

The pressure sensitive adhesive tapes market key players in the pressure sensitive adhesive tapes market include 3M (US), tesa SE (Germany), Nitto Denko Corporation (Japan), Lintec Corporation (Japan), Intertape Polymer Group, (IPG) Inc (Canada), Avery Dennison Corporation (US), Lohmann GmbH & Co., KG (Germany), Berry Global Inc (US), Scapa Group plc (UK), Saint-Gobain Performance Plastics (France), Nichiban Co., Ltd (Japan).

3M: 3M, a renowned technology company specializing in the manufacturing of industrial, safety, and consumer products, operates across several key segments: Safety and Industrial, Transportation and Electronics, Health Care, Consumer, and Corporate and Unallocated. The Safety and Industrial segment encompasses a wide range of products such as personal safety gear, industrial adhesives and tapes, abrasives, closure and masking systems, electrical components, automotive aftermarket solutions, and roofing granules. In the Transportation and Electronics sector, 3M offers products for electronics, automotive and aerospace applications, commercial solutions, advanced materials, and transportation safety. The Health Care segment focuses on providing medical and surgical supplies, skin health and infection prevention products, oral care solutions, separation and purification sciences, health information systems, inhalation and transdermal drug delivery systems, and food safety products. The Consumer segment covers various consumer-oriented categories including healthcare, home care, home improvement, and stationery and office products. This includes a range of items such as consumer bandages, braces, supports, respirators, cleaning products, retail abrasives, picture hanging solutions, and consumer air quality products.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pressure Sensitive Adhesive Tapes Market to Boost Revenue Potential, Highlight Latest Development and Develop Important Players Profile

Alexey Troshin of NRG Group Announces Strategic Shift

There’s big news regarding the latest development as Alexey Troshin of the NRG Group steps back from Smart Batteries, a part of the group. This decision marks a significant shift as Troshin sets his sights on new and ambitious projects in public transport industry. The industry is experiencing a significant boom associated with the introduction of new technologies, primarily the electrification of public transport, as well as in connection with the active use of financing mechanisms through concession agreements.

This is especially the case when one of the key players such as Alexey Troshin leaves Smart Batteries. Troshin has always stressed the need to constantly develop and search for new ways in business, which is quite characteristic of him.

Thanks to Alexey Troshin, the NRG Group has grown into a large diversified holding that operates in many areas. His strategic vision and ability to adapt to changing market dynamics have been key to the group’s sustained growth.

A Visionary Entrepreneur

Born in Yuzhno-Sakhalinsk, he moved to Moscow for higher education and quickly became involved in various business ventures. The early years in trading and small commercial businesses helped shape his future accomplishments. Before establishing the NRG Group, Troshin had a good understanding of the market and was able to seize profitable business opportunities.

The key moment in Troshin’s career was his choice to concentrate on distributed energy and the creation of small and mobile power facilities. This strategic move made the NRG Group take advantage of the new opportunities within the energy market and place the company at the forefront of the new energy techniques. Troshin’s emphasis on sustainability and decarbonization has also been a driving force behind the group’s initiatives.

Strategic Exit from Smart Batteries

The decision to exit Smart Batteries allows Alexey Troshin to dedicate his efforts to new ventures within the NRG Group. Smart Batteries have been a significant part of the holding, contributing to its growth and innovation. Nevertheless, Troshin has a rather ambitious strategic vision based on constant expansion and searching for new opportunities and horizons in the sphere of energy.

Future Plans and Innovations

Looking beyond SMART Batteries, Alexey Troshin is focused on leveraging his extensive experience and strategic insights to explore new projects that align with his vision for the future. His passion for sustainability, innovation, and technology will definitely influence the path that these new ventures will take. This has always been a characteristic of Troshin with regard to entrepreneurship as he is always able to predict the future trends of the market and adjust accordingly.

Media Contact
Company Name: Alexey Troshin
Contact Person: Alexey Troshin
Email: Send Email
Country: Russian Federation
Website: https://nyweekly.com/lifestyle/alexey-troshin-lessons-learned-for-avoiding-business-mistakes/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Alexey Troshin of NRG Group Announces Strategic Shift

Adrián Trejo, the entrepreneur aiming to redefine neurodiversity care in the United States

Barcelona – October 3, 2024 – Adrián Trejo de la Rosa, CEO and co-founder of Xtraordinary People, leads an innovative project aiming to revolutionize neurodiversity care. After achieving success in Spain, Trejo is now poised to bring this model to the United States with the goal of transforming how neurodivergence is approached.

Trejo explains that the inspiration for this project came from observing that “neurodivergent individuals were not receiving the comprehensive support they need”. He points out that the development of these individuals is deeply connected to their family, educational, and social environments, yet he laments that “these aspects are rarely integrated into conventional treatments”. To fill this gap, Xtraordinary People has developed a bio-psycho-social approach that encompasses all these areas, enabling neurodivergent individuals to fully realize their potential.

Unlike traditional approaches, Trejo highlights that his organization distinguishes itself with its holistic methodology. This method not only addresses medical aspects but also actively involves the family, school, and community. The multidisciplinary team at Xtraordinary People works on creating individualized treatments that offer rapid diagnoses and immediate access to therapies. “We don’t treat neurodiversity as a deficit – Trejo asserts-, but as a natural expression of human diversity that should be understood and valued”.

Expansion to the United States: a key step

According to Trejo, the expansion to the United States represents a crucial opportunity for the organization. “We aim to open 10 centers in the U.S. by 2025”, he says, emphasizing that partnerships with universities and research centers will be essential for developing new therapies. His vision is to overcome “the barriers faced by neurodivergent individuals, especially in coordinating between family, educational, and medical environments”. With this, Trejo hopes to establish Xtraordinary People as a leader not only in clinical treatment but also in social inclusion.

Innovation at Xtraordinary People is grounded in collaboration with prestigious international institutions such as the Spanish neuroscience company Synaptia Health Projects, Mexico’s National Institute of Neurology and Neurosurgery ‘Manuel Velasco Suárez’ (INNN), Spain’s Rey Juan Carlos University, and the Spanish National Research Council (CSIC). These alliances help develop advanced biotechnological solutions for neurodiversity care.

The approach centers on research and the use of emerging technologies such as artificial intelligence and data analysis to provide more precise diagnoses and personalized treatments. Thanks to this continuous collaboration, Xtraordinary People remains at the forefront of neuroscience, ensuring constant improvement in its methods and contributing to global advancements in neurodiversity care.

Commitment to Inclusive environments

Social inclusion is another fundamental pillar of Xtraordinary People’s approach. Trejo stresses that his organization “goes beyond medical care” with the aim of creating environments where neurodivergent individuals are understood and included in their families, communities, and workplaces. To achieve this, Xtraordinary People offers training for educators, support for families, and tools that facilitate the employment of neurodivergent individuals.

Finally, Trejo shares a hopeful message for families living with neurodiversity: “Neurodiversity is not a limitation, but a natural variation of the human experience”. He emphasizes that families are not alone in this journey and that “eliminating stigma and creating inclusive environments” is essential for neurodivergent individuals to reach their full potential. Trejo assures that “Xtraordinary People is committed to leading this change by providing the necessary support and promoting a culture of inclusion”.

Media Contact
Company Name: SYNAPTIA HEALTH GROUP SL
Contact Person: Press Office
Email: Send Email
Country: United States
Website: https://www.xtraordinarypeople.io/

Winnie the Pooh Meets the Bible: A Heartwarming Christmas Tale for the Whole Family

Discover the Joy of the True Meaning of Christmas with Pooh Bible

Charleston, West Virginia – Oct 3, 2024 – In an enchanting twist on a beloved classic, Pooh Bible brings the timeless characters of Winnie the Pooh into a heartwarming story about the true meaning of Christmas. This captivating adventure, perfect for families and readers of all ages, seamlessly combines the whimsy of A.A. Milne’s characters with the profound message of the Bible. Pooh Bible is now available at PoohBible.com, offering a delightful and entertaining Christmas tale that is sure to be the most enjoyable holiday story of the year.

In this unique narrative, Christopher Robin returns from Sunday School eager to share the message of Christmas with his friends in the Hundred Acre Wood. As he explains the birth of Jesus, Winnie the Pooh, Piglet, Tigger, and the rest of the gang decide to throw a birthday party for Jesus. However, their journey to find the perfect gifts for the King leads them to a deeper understanding of what truly matters. In a touching conclusion, the characters realize that the greatest gift they can offer is their love.

With original artwork from the 1924 Winnie the Pooh stories, the Pooh Bible captures the nostalgic charm and beloved personalities that have captivated readers for nearly a century. Fans will be delighted to hear the familiar voices of Pooh, Piglet, Tigger, and friends come to life as they journey through this endearing Christmas story.

“Pooh Bible beautifully blends the joy of childhood with the profound message of God’s love, making it a perfect read for families during the holiday season,” said John Vantana, creator of Pooh Bible. “We hope this story becomes a treasured part of family traditions for years to come.”

For more information visit PoohBible.com. Embrace the spirit of Christmas with this delightful fusion of classic literature and biblical teaching, and share the message of love, faith, and joy with your loved ones.

About Pooh Bible:

Pooh Bible is a fun and family-friendly project that reimagines the beloved world of Winnie the Pooh with biblical stories, offering entertaining and meaningful tales for all ages. Featuring original illustrations and heartfelt storytelling, Pooh Bible promises to bring joy and inspiration to readers of every generation.

About the Author:

John Vantana is a dedicated storyteller with a vision to spread the love of Christ through creative narratives that resonate with audiences of all ages. His latest work, Winnie the Pooh’s Christmas Adventure, offers a unique blend of classic characters and spiritual wisdom, aimed at sharing the message of God’s love during the holiday season. Through his storytelling, Vantana is on a mission to reach 1 billion souls worldwide, encouraging readers to reflect on the true meaning of Christmas and the gift of faith.

Media Contact
Company Name: John Vantana
Contact Person: John Vantana
Email: Send Email
Phone: 3048127442
Address:289 Blaine Dr.
City: Evans
State: WV 25241
Country: United States
Website: www.PoohBible.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Winnie the Pooh Meets the Bible: A Heartwarming Christmas Tale for the Whole Family

Skoshart.com: Revolutionizing Digital Art and Design with Creativity, Community, and Innovation

Skoshart.com, a dynamic new platform dedicated to bringing digital art to life, is excited to announce its official launch, offering a unique space for artists, designers, and enthusiasts to explore, create, and share their work with a global audience. Combining innovative tools, a vibrant community, and a deep appreciation for artistic expression, Skoshart.com promises to become a go-to destination for creative people and hobbyists alike.

A New Era in Digital Art

At its core, Skoshart.com is a digital art platform(online editor) that strives to make artistic creation accessible to everyone. Whether They’re a professional artist, a student learning digital design, or simply someone who enjoys the creativity, Skoshart.com is designed to inspire. The platform offers a wide range of digital tools that allow artists to create high-quality art and designs, from sketches and illustrations to complex digital paintings and graphic design projects. With intuitive user interfaces and cutting-edge technology, Skoshart.com ensures that artists of all levels can produce impressive results without technical barriers.

“Skosh” – A Touch of Art in Every Design

The name “Skosh” is derived from the Japanese word “sukoshi,” meaning “a little” or “a small amount”. True to its name, Skoshart.com aims to bring that perfect touch of creativity and flair to every design. The platform encourages users to explore the subtle details and small creative flourishes that can make a piece of art truly unique. Skoshart.com embraces the idea that sometimes, a small addition can completely transform a design, inspiring a fresh and innovative perspective.

A Tools for Everyone

Skoshart.com offers a free suite of powerful tools designed to support all types of digital creators. Whether working on a mobile device, tablet, or desktop, artists will have access to customizable brushes, color palettes, and layer systems that rival traditional software. The platform integrates AI-assisted design tools, allowing users to streamline their workflow and experiment with new techniques. Artists can also collaborate on projects in real time, enabling teams of creators to work together from anywhere in the world.

“Skoshart’s mission is to empower anyone, anywhere, to bring their creative vision to life. Create free, without limits,” said Andrius, Founder and CEO of Skoshart.com. “An online editor where design isn’t restricted by cost, skill level, or geography. Whether user’re a professional designer or someone who’s just starting to dabble in digital art, They want to be the place where user ideas come to life at no cost.”

Easy-to-Use Templates for Every Artist

Skoshart.com is dedicated to simplifying the creative process with its extensive library of free, customizable templates. Whether users are looking to create logotypes, digital illustrations, social media graphics, editor offers a wide selection of professionally designed templates that can be easily edited and personalized to fit any project. These templates are ideal for people who want to save time on design fundamentals and jump straight into personalizing designs.

Each template is fully customizable, allowing users to modify colors, typography, and images with just a few clicks. With drag-and-drop functionality and intuitive editing tools, users of all skill levels can create professional-quality work in minutes. These ready-made templates not only reduce the time it takes to complete projects but also inspire users by offering a creative starting point. Whether user’re a seasoned designer or a newcomer to digital art, the templates on Skoshart.com make the creative process accessible and enjoyable for everyone.

“They believe that creativity should be effortless, and their templates give users the tools to transform their ideas into stunning visuals quickly,” said Andrius.

Accessibility and Affordability

Skoshart.com is committed to making online editor and tools free and accessible. Without plans or membership tiers, users can sign in and start creating.

“They wanted to create a platform that’s inclusive and accessible to everyone, regardless of their financial situation. That’s why they’ve built Skoshart.com with just one free option, ensuring that cost is never a barrier to creativity,” added Andrius.

Looking Ahead

As Skoshart.com continues to grow, the team is excited about future developments and partnerships. With plans to expand its educational offerings, introduce new tools, and collaborate with industry leaders, Skoshart.com is poised to become a central hub for digital art and design.

For more information or to start creating, visit Skoshart.com and follow the platform on social media for updates, tips, and inspiration.

Media Contact
Company Name: Skoshart
Contact Person: Andrius M
Email: Send Email
Country: United States
Website: Skoshart.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Skoshart.com: Revolutionizing Digital Art and Design with Creativity, Community, and Innovation

IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight

“IgA nephropathy Clinical Trials”

IgA nephropathy companies working in the market are Apellis Pharmaceuticals, BioCryst Pharmaceuticals, Vera Therapeutics, Inc., MorphoSys, Omeros Corporation, Arrowhead Pharmaceuticals, Chinook Therapeutics, Takeda, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Eledon Pharmaceuticals, Novartis, RemeGen, Travere Therapeutics, Rohto Pharmaceutical, Ionis Pharmaceuticals, Otsuka Pharmaceutical, Jiangsu HengRui Medicine Co., Ltd., Guangdong Hengrui Pharmaceutical., Others.

(Albany, USA) IgA nephropathy pipeline report showcase a robust space with 30+ key companies working to develop 30+ pipeline therapies for IgA nephropathy treatment.

DelveInsight’s ‘IgA Nephropathy Pipeline Insight 2024’ report provides comprehensive global coverage of available, marketed, and pipeline IgA nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the IgA nephropathy pipeline domain.

To know more about the IgA Nephropathy Pipeline report offerings, click here @ IgA Nephropathy Pipeline Analysis

Key Takeaways from the IgA Nephropathy Pipeline Report

DelveInsight’s IgA nephropathy pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for IgA nephropathy treatment.
Leading IgA nephropathy companies working in the treatment market are Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.
Some of the IgA nephropathy drugs in various phases of development are BION-1301, Telitacicept, LNP023, HR19042, IONIS-FB-LRx, Atacicept, Atrasentan, AT-1501, SHR-2010, OMS721, Sibeprenlimab, Cemdisiran, Felzartamab, ADR-001, Ravulizumab, ALXN2050, APL-2, ARO-C3, Mezagitamab, Sparsentan, BCX9930, TST 004, AP 305, AP 308, DM199, KP104, ALPN-303, and others.
In April 2024, European Commission (EC) granted conditionalmarketing authorization (CMA) to FILSPARI for the treatment ofadults with primary IgAN with a urine protein excretion ≥1.0 g/day(or urine protein-to-creatinine ratio ≥0.75 g/g).
In March 2024, Travere therapeutics/Vifor Pharma announced thesubmission of a sNDA to the US FDA for conversion of its accelerated approvalof FILSPARI to full approval. In addition to this, recently in April 2024, theEuropean Commission granted CMA for FILSPARI for the treatment of adultswith primary IgAN.
In October 2023, Novartis announced positive top-line results from the pre-specified interim analysis of the Phase III APPLAUSEIgAN study (NCT04578834) at 9 months. Submission for possible accelerated approval to the FDA was accepted and has received priority review. The study is to evaluate iptacopan’s ability to slow IgAN progression by measuring estimated glomerular filtration rate (eGFR) slope over 24 months with topline results expected in 2025.
In June 2023, Chinook Therapeutics, Inc. announced that it has entered into an agreement and plan of merger withNovartis AG pursuant to which Novartis will acquire Chinook for $40 per share in cash, or a total of $3.2 billion.
On November 05, 2022, Vera Therapeutics, Inc. announced new clinical data presented on the Company’s two product candidates, atacicept in immunoglobulin A nephropathy (IgAN) and MAU868 in kidney transplant. These data were presented in poster and oral presentations, respectively, at the American Society of Nephrology (ASN) Kidney Week 2022 Annual Meeting, held November 3-6, 2022, in Orlando, Florida.
In October 2022, Transcenta Holding Limited announced that TST004, its best-in-class, humanized monoclonal antibody targeting MASP2, had received IND clearance from the U.S. Food and Drug Administration (FDA). MASP2, mannose-binding protein-associated serine protease 2, is a key enzyme in the lectin pathway initiation of complement activation. Studies have shown that lectin pathway activation contributes to multiple human diseases such as immunoglobulin A nephropathy (IgAN), hematopoietic stem-cell transplantation–associated thrombotic microangiopathy (HSCT-TMA). Therefore, inhibition of MASP2 might be a potential treatment approach for diseases related to lectin pathway activation.
In September 2022, Eledon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had cleared the company’s Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).
In August 2022, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had lifted its partial clinical hold on the BCX9930 program. The company will resume enrollment in global clinical trials under revised protocols at a reduced dose of 400 mg twice daily of BCX9930. This includes the REDEEM-1 and REDEEM-2 pivotal trials in patients with paroxysmal nocturnal hemoglobinuria (PNH) and the RENEW proof-of-concept trial in patients with C3 glomerulopathy (C3G), immunoglobulin A nephropathy (IgAN) and primary membranous nephropathy (PMN).

Get a Free Sample PDF Report to know more about IgA Nephropathy Pipeline Therapeutic Assessment- IgA Nephropathy Treatment Market

IgA Nephropathy Overview

IgA nephropathy, also known as Berger’s disease, is a chronic kidney disorder characterized by the deposition of immunoglobulin A (IgA) in the glomeruli, the filtering units of the kidneys. This deposition triggers inflammation, leading to progressive kidney damage. The exact cause of IgA nephropathy remains unclear, but it is thought to involve a combination of genetic predisposition, abnormal immune response, and environmental factors.

Patients with IgA nephropathy often present with recurrent episodes of hematuria (blood in the urine), which may be visible or detected microscopically. Other symptoms can include proteinuria (protein in the urine), hypertension, and, in advanced cases, swelling in the legs and feet due to fluid retention. Diagnosis is confirmed through kidney biopsy, which reveals the characteristic IgA deposits.

The progression of IgA nephropathy varies widely among individuals. Some may experience only mild disease with stable kidney function, while others may progress to end-stage renal disease requiring dialysis or transplantation. Management focuses on controlling blood pressure, reducing proteinuria, and slowing disease progression through medications such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs). Emerging treatments, including targeted immunotherapies, are currently under investigation to provide better outcomes for patients with this challenging condition.

Request for a sample report @ https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight

IgA Nephropathy Pipeline Drugs mentioned in the report:

Sparsentan: Travere Therapeutics
Atrasentan: Chinook Therapeutics
LNP023: Novartis Pharmaceuticals
HR19042: Jiangsu HengRui Medicine Co., Ltd.
ADR-001: Rohto Pharmaceutical Co., Ltd.
And Many Others

Learn more about the IgA nephropathy clinical trials advancements @ IgA Nephropathy Drugs in Pipeline

IgA Nephropathy Therapeutics Assessment

The IgA nephropathy pipeline report proffers an integral view of IgA nephropathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the IgA Nephropathy Pipeline Report

Coverage: Global
IgA Nephropathy Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
IgA Nephropathy Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
IgA Nephropathy Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
IgA Nephropathy Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
IgA Nephropathy Therapeutics Assessment By Mechanism of Action: Endothelin A receptor antagonists, Angiotensin type 1 receptor antagonists, Bacteria replacements, Gastrointestinal microbiome modulators, Opioid kappa receptor antagonists, Opioid mu receptor agonists, Serotonin 3 receptor antagonists
Key IgA Nephropathy Companies: Chinook Therapeutics, Inc., RemeGen Co., Ltd., Novartis, Jiangsu HengRui Medicine Co., Ltd., Ionis Pharmaceuticals, Inc., Vera Therapeutics, Inc., Eledon Pharmaceuticals, Guangdong Hengrui Pharmaceutical Co., Ltd, Omeros Corporation, Otsuka Pharmaceutical, Alnylam Pharmaceuticals, MorphoSys AG, Rohto Pharmaceutical, Alexion Pharmaceuticals, Apellis Pharmaceuticals, Inc., Arrowhead Pharmaceuticals, Takeda, Travere Therapeutics, BioCryst Pharmaceuticals, Transcenta Holding, Shanghai Alebund Pharmaceuticals, DiaMedica Therapeutics, SELECTA BIOSCIENCES, Kira Pharmaceuticals, Alpine Immune Sciences, and others.
Key IgA Nephropathy Pipeline Therapies: BION-1301, Telitacicept, LNP023, HR19042, IONIS-FB-LRx, Atacicept, Atrasentan, AT-1501, SHR-2010, OMS721, Sibeprenlimab, Cemdisiran, Felzartamab, ADR-001, Ravulizumab, ALXN2050, APL-2, ARO-C3, Mezagitamab, Sparsentan, BCX9930, TST 004, AP 305, AP 308, DM199, KP104, ALPN-303, and others.

Request for a sample report @ https://www.delveinsight.com/report-store/iga-nephropathy-igan-pipeline-insight

Table of Contents

1. IgA Nephropathy Pipeline Report Introduction

2. IgA Nephropathy Pipeline Report Executive Summary

3. IgA Nephropathy Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. IgA Nephropathy Clinical Trial Therapeutics

6. IgA Nephropathy Pipeline: Late Stage Products (Pre-registration)

7. IgA Nephropathy Pipeline: Late Stage Products (Phase III)

8. IgA Nephropathy Pipeline: Mid Stage Products (Phase II)

9. IgA Nephropathy Pipeline: Early Stage Products (Phase I)

10. IgA Nephropathy Pipeline Therapeutics Assessment

11. Inactive Products in the IgA Nephropathy Pipeline

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key IgA Nephropathy Companies

14. Key Products in the IgA Nephropathy Pipeline

15. IgA Nephropathy Unmet Needs

16. IgA Nephropathy Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: IgA nephropathy Clinical Trials 2024 (Updated): FDA Approvals, Pipeline, Medication, Therapies, Treatment Market and Companies by DelveInsight

AfriKin Art Fair 2024, Themed ‘Threads of Life in Fragments of Time’, Will Celebrate International Art and Celebrate the Interconnections of Humanity and the Universe

Presented by AfriKin and the City of North Miami, this year’s events mark the 10th year of the AfriKin Art Fair in Miami, Florida. AfriKin invites people to view African art with an emphasis on dimensions of time and space.

AfriKin, the Miami-based 501(c)3 nonprofit organization that focuses on creating cultural connections through immersive and engaging artistry, in partnership with the City of North Miami and the North Miami Community Redevelopment Agency (CRA), is thrilled to present AfriKin Art Fair 2024. This is the event’s 10th year running and will feature a theme of ‘Threads of Life in Fragments of Time.’

Guests will be inspired to introspect their place in the world around them as they view a showcase of African contemporary art that explore the connections that draw humans, the earth, and the cosmos together and define them. Furthermore, themes of displacement, regeneration, healing, and environmental challenges will be illuminated through various mediums including visual art, performance art, photography, and interactive digital installation.

An immersive climate change installation titled ‘Submerged Sentience’ will be a centerpiece to this year’s event and will feature an interactive series of photographs, films, and reenactments. Viewers will engage with issues such as water scarcity, rising sea levels, and climate change – issues that not only impact Global Africa but also people around the world. Other installations will include an exploration of African ecosystems entitled ‘Delta’s Roar’ and ‘The Salted Language’, a poetic narrative underscoring the deep correlation between environmental destruction and cultural erosion.

The AfriKin Art Fair 2024 will also feature artist talks on inclusivity, the power of art to transcend barriers, and the rallying call to support those in adversity. A global fashion runway will showcase designers from countries around the world. AfriKin will also honor Miami-Dade police and firefighters through ‘AfriKin: Guardians of Time: An Evening of Art and Honor for Miami-Dade First Responders.’ First responders can see more at https://afrikin.art/guardians-of-time/.

Credit: artist Angèle Etoundi Essamba

According to Alfonso Brooks, founder of AfriKin, “The goal of this year’s theme is to unpack the role of art and culture in sustainable development; both are endangered, and we must use every voice to join the fight for a better world. As our slogan says, creative expressions are the foundation of liberation.”

This highly anticipated event will be held at Maison AfriKin in the Scott Galvin Community Center (1600 NE 126th St., North Miami, FL 33181) on December 1st-8th, 2024, from 11am-7pm each day. For tickets and further information, please visit https://afrikin.art/. See the promo at https://vimeo.com/1013336456.

ABOUT AFRIKIN

AfriKin is a Miami, Florida, based 501(c)3 nonprofit organization creating cultural connections via masterful artistry and meaningful conversations. Learn more by visiting https://afrikin.org/. Follow AfriKin on social media:

Facebook: @afrikinnation

Instagram: @afrikinnation

Twitter/X: @afrikinnation

Media Contact
Company Name: AfriKin
Contact Person: Alfonso Brooks
Email: Send Email
Phone: 305-900-5523
City: MIAMI
State: FLORIDA
Country: United States
Website: https://afrikin.art/